Patel Gaurang, Chougule Mahavir, Singh Mandip, Misra Ambikanandan
TIFAC-CORE in NDDS, Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, Gujarat, India.
Methods Enzymol. 2009;464:167-91. doi: 10.1016/S0076-6879(09)64009-X.
Liposomal dry powder formulations (DPFs) have proven their superiority over conventional DPFs due to favorably improved pharmacokinetics and pharmacodynamics of entrapped drugs, and thus, reduced local and systemic toxicities. Nanoliposomal DPFs (NLDPFs) provide stable, high aerosolization efficiency to deep lung, prolonged drug release, slow systemic dilution, and avoid macrophage uptake of encapsulated drug by carrier-based delivery of nano-range liposomes. This chapter describes methods of preparation of nanoliposomes (NLs) and NLDPFs, using various techniques, and their characterization with respect to size distribution, flow behavior, in vitro drug release profile, lung deposition, cellular uptake and cytotoxicity, and in vivo pharmacokinetics and pharmacodynamics. Some examples have been detailed for better understanding of the methods of preparation and evaluation of NLDPFs by investigators.
脂质体干粉制剂（DPFs）已证明其优于传统DPFs，因为包封药物的药代动力学和药效学得到了有利改善，从而降低了局部和全身毒性。纳米脂质体DPFs（NLDPFs）为肺部深处提供稳定、高气雾化效率、延长药物释放、缓慢的全身稀释，并通过基于载体的纳米级脂质体递送避免巨噬细胞摄取包封药物。本章描述了使用各种技术制备纳米脂质体（NLs）和NLDPFs的方法，以及它们在尺寸分布、流动行为、体外药物释放曲线、肺部沉积、细胞摄取和细胞毒性以及体内药代动力学和药效学方面的表征。为便于研究人员更好地理解NLDPFs的制备和评估方法，列举了一些实例。
